A Multi-omics Study of Epithelial Ovarian Cancer

NCT03742856 | Unknown DMC

• 1 other identifier: EOC-OMICS
• Study Type: observational
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to analyze the multi-omics results between epithelial ovarian cancer (EOC) patient with different FIGO stages and pathological subtypes. The multi-omics profiles include whole exome sequencing, analysis of transcriptomics and metabolomics. A comprehensive multi-omics will reveal the invasiveness and tumorigenesis of EOC.

Conditions

Epithelial Ovarian Cancer; Tumor Invasiveness; Whole Exome Sequencing; Transcriptomics; Metabolomics; Tumorigenesis

Outcome Measures

Primary Outcomes (1)

• Frequencies of somatic driving mutations

  The differences of frequencies of somatic driving mutations will be compared between patients of different FIGO stages and different pathological subtypes.

  Two years

Secondary Outcomes (3)

• Frequencies of alteration of RNA expression

  Two years

• Frequencies of alteration of protein expression and signal pathway

  Two years

• Progression-free survival

  Five years

Interventions

A multi-omics analysis COMBINATION_PRODUCT

A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics.

Eligibility Criteria

• Sex: female
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients confirmed primary epithelial ovarian cancer will be included for analysis.

You may qualify if:

• Confirmed primary epithelial ovarian cancer
• Signed an approved informed consents
• Feasible for biopsy

Sponsors & Collaborators

• Lei Li: lead

Study Sites (1)

Lei Li

Beijing, Beijing Municipality, 100730, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

An 8 ml peripheral venous blood, and 50 μL cancer tissue and tissue adjacent to cancer will be collected from eligible patients.

MeSH Terms

Conditions

Carcinoma, Ovarian Epithelial; Carcinogenesis

Condition Hierarchy (Ancestors)

Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Ovarian Neoplasms; Endocrine Gland Neoplasms; Neoplasms by Site; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders; Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Lei Li, M.D.

  Peking Union Medical College Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Lei Li, M.D.

CONTACT

13911988831; lileigh@163.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: November 9, 2018
• First Posted: November 15, 2018
• Study Start: November 10, 2018
• Primary Completion: November 23, 2020
• Study Completion: November 23, 2020
• Last Updated: November 15, 2018

Record last verified: 2018-11

Locations

CN (1)